secwatch / observer
8-K filed March 20, 2026, 7:59 PM ET ticker ONCY CIK 0001129928
other material confidence high sentiment neutral materiality 0.35

Oncolytics completes continuance to BC; expects Nevada domestication by March 31

ONCOLYTICS BIOTECH INC

item 3.03item 5.03item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001104659-26-032763
form_type
8-K
ticker
ONCY
cik
0001129928
company_name
ONCOLYTICS BIOTECH INC
filed_at
2026-03-20T23:59:59+00:00
discovered_at
2026-05-14T18:02:34.594808+00:00
generated_at
2026-05-15T09:27:08.433830+00:00
sec_items
["3.03", "5.03", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.35
calibrated_materiality_score
0.35
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001104659-26-032763
json_url
https://secwatch.observer/filing/0001104659-26-032763.json
markdown_url
https://secwatch.observer/filing/0001104659-26-032763.md
text_url
https://secwatch.observer/filing/0001104659-26-032763.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/0001104659-26-032763-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/tm269428d1_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

fa6fd44d4cfd74b8b7e4b9f51b1d35a6f9142ed2

ONCOLYTICS BIOTECH INC: Adopted continuation application with new Notice of Articles and Articles of Oncolytics British Columbia, changing governing documents from Alberta to British Columbia corporate law.

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

IOT

Samsara Inc. reincorporates from Delaware to Nevada, effective June 1, 2026

Samsara Inc. June 1, 2026, 4:07 PM ET other_material Items 3.03, 5.03, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) became effective on June 1, 2026, at 12:02 a.m. Pacific Time

Filing page SEC filing

Clearway Energy LLC

Clearway Energy LLC converts Class A units to Class C units with no economic impact

Clearway Energy LLC May 1, 2026, 7:59 PM ET other_material Items 3.03, 5.03, 9.01

same fact type: governance_change same SEC item: 3.03, 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

In connection with the Class A Stock Conversion, on May 1, 2026, Clearway, Inc. and Clearway Energy Group LLC amended and restated the Fourth Amended and Restated Limited Liability Company Agreement of the Company by entering into a Fifth Amended and Restated Limited Liability Company Agreement of the Company (the “Fifth Amended Company Agreement”).

Filing page SEC filing

WORLDS INC

Worlds Inc. changes name to Gemaxel Inc., effective March 26, 2026

WORLDS INC June 1, 2026, 2:59 PM ET other_material Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

On March 26, 2026 the Company amended ARTICLE FIRST of its Certificate of Incorporation and changed its name to Gemaxel Inc. from Worlds Inc.

Filing page SEC filing

BTCS

BTCS reduces stockholder quorum requirement from majority to 33.3%

BTCS Inc. June 1, 2026, 9:29 AM ET other_material Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

On May 29, 2026, the board of directors of BTCS Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”) and adopted an amendment to the quorum requirement contained in Article II, Section 2.9 of the Bylaws (the “Amendment”) to provide that the holders of thirty-three and one third percent (33.3%) of the voting power of the Company entitled to vote at a meeting of stockholders, present in person or represented by proxy, shall constitute a quorum for the transaction of business.

Filing page SEC filing

MRNA

Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors

Moderna, Inc. May 11, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.

Filing page SEC filing

LKQ

LKQ stockholders approve 25% special meeting right; all director nominees elected

LKQ CORP May 8, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

the Company’s stockholders, upon the recommendation of the Company’s board of directors (the “Board”), approved an amendment (the “Charter Amendment”) to the Company’s Restated Certificate of Incorporation to provide stockholders holding a combined 25% or more of the Company’s common stock with the right to request a special meeting of stockholders.

Filing page SEC filing

ENTG

Entegris shareholders eliminate supermajority voting; all directors elected

ENTEGRIS INC May 8, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

On February 5, 2026, the Board approved the adoption of the Amended and Restated By-Laws of the Company to conform to the Second Amended and Restated Certificate of Incorporation. The Board’s approval of the Amended and Restated By-Laws was contingent upon the stockholders’ approval of the Second Amended and Restated Certificate of Incorporation. The Amended and Restated By-Laws became effective on May 7, 2026.

Filing page SEC filing

MAN

ManpowerGroup declares $0.72 dividend; shareholders approve equity plan amendment and director removal without cause

ManpowerGroup Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 5.07, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)

Comparable filing

the Board of Directors of the Company amended Section 3.3 of Article III of the Company’s Amended and Restated By-Laws (the “ By-Laws Amendment ”) to permit the removal of a director with or without cause by the affirmative vote of two-thirds of the outstanding shares of capital stock of the Company entitled to vote at a meeting of shareholders duly called for such purpose. The effective date of the By-Laws Amendment is May 8, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001104659-26-032763
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.